Health

Value-based healthcare in France: A slow adoption of cost-effectiveness criteria

December 08, 2015

Europe

Value-based healthcare in France

December 08, 2015

Europe
Martin Koehring

Senior Manager for Sustainability, Climate Change and Natural Resources & Head of the World Ocean Initiative

Martin Koehring is senior manager for sustainability, climate change and natural resources at (part of The Economist Group). He leads Economist Impact's sustainability-related policy and thought leadership projects in the EMEA region. He is also the head of the, inspiring bold thinking, new partnerships and the most effective action to build a sustainable ocean economy.

He is a member of the Advisory Committee for the UN Environment Programme’s Global Environment Outlook for Business and is a faculty member in the Food & Sustainability Certificate Program provided by the European Institute for Innovation and Sustainability.

His previous roles at The Economist Group, where he has been since 2011, include managing editor, global health lead and Europe editor at The Economist Intelligence Unit.

He earned a bachelor of economic and social studies in international relations from Aberystwyth University and a master’s degree in diplomacy and international relations from the College of Europe.

Contact

This new Economist Intelligence Unit (EIU) report, commissioned by Gilead Sciences, explores important questions about the French healthcare system. How is healthcare innovation assessed in France? To what extent is value for money influencing price negotiations with the pharmaceutical industry? Are national guidelines being adhered to in shaping France’s healthcare delivery?

Key findings

  • In France, the level of improvement is a key determinant rather than price in deciding how innovation is valued.
  • Patient access to new drugs is highly valued and influential in how the French healthcare system is organised.
  • A lack of transparency in the way in which final prices for new drugs are negotiated curbs progress of value-based healthcare in France.
  • A lack of consistency in healthcare providers’ observance of official prescribing guidelines are also making it more complicated to assess the extent to which French health authorities are getting real value for money.
  • Economic evaluation has been part of the reimbursement and pricing process for the most innovative medicines since 2013. However, cost-effectiveness criteria are not yet a key consideration in the process.
  • French citizens' insurance contributions create high expectations in the delivery of cutting-edge treatments.

Further reading:

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week